Celsion Corp. (CLSN)
-NasdaqCM 1.01 
0.07(7.44%) May 17, 4:00PM EDT|After Hours
:
1.01 0.00 (0.00%) May 17, 7:58PM EDT
| Prev Close: | 0.94 |
|---|
| Open: | 1.03 |
|---|
| Bid: | 1.00 x 2900 |
|---|
| Ask: | 1.05 x 1500 |
|---|
| 1y Target Est: | 1.00 |
|---|
| Beta: | 1.4 |
|---|
| Next Earnings Date: | 9-Aug-13 |
|---|
| Day's Range: | 0.99 - 1.09 |
|---|
| 52wk Range: | 0.75 - 9.44 |
|---|
| Volume: | 5,755,879 |
|---|
| Avg Vol (3m): | 2,277,940 |
|---|
| Market Cap: | 43.42M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.69 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- CELSION CORP FinancialsEDGAR Online Financials(Fri, May 17)
- GM Initiates Cadillac Recall, InterOil Gets Offer For Elk Stake, and 3 More Hot Stocksat Wall St. Cheat Sheet(Fri, May 17)
- InPlay: Celsion's ThermoDox HEAT study findings reviewed at the 9th Annual World Conference on Interventional Oncology; Duration of RFA procedure correlates with an overall survival benefitBriefing.com(Fri, May 17)
- Celsion's ThermoDox® HEAT Study Findings Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO)PR Newswire(Fri, May 17)
- Amarin & Celsion: Post-Earnings Roundupat Seeking Alpha(Wed, May 15)
- Celsion's Q1 Call: What You Need To Knowat Seeking Alpha(Thu, May 9)
- Celsion Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Celsion: New Findings Show Act Of Desperationat Seeking Alpha(Thu, May 9)
- Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business UpdatePR Newswire(Thu, May 9)
- Q1 2013 Celsion Corp Earnings Release - Before Market OpenCCBN(Thu, May 9)
- CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Thu, May 9)
- Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potentialat Seeking Alpha(Fri, May 3)
- Celsion's A Fighterat Seeking Alpha(Wed, May 1)
- Celsion Announces ThermoDox® HEAT Study Findings to be Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO) in New York City on May 16, 2013PR Newswire(Wed, May 1)
- Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013PR Newswire(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 323.36 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.39 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.12 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology.
View More